Search the Newsreel

Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Aristotle Capital Management LLC

Aristotle Capital Management LLC decreased its stake in Jazz Pharmaceuticals PLC by 17.8% in Q1 2026, selling over 28,000 shares. Despite this, other institutional investors like Franklin Resources Inc., Bank of New York Mellon Corp, and Adage Capital Partners GP L.L.C. significantly increased their …

AZZ Inc (AZZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of AZZ Inc (AZZ), detailing its price momentum, support and resistance levels, and key technical indicators. It presents a summary of buy, neutral, and sell signals from various indicators like MACD, RSI, and moving averages, along with an …

Jazz Pharmaceuticals Reports Outcomes of 2026 Annual General Meeting with Strong Shareholder Backing

Jazz Pharmaceuticals plc held its 2026 Annual General Meeting where shareholders showed strong support for key proposals, including board nominations and the appointment of auditors. This outcome suggests continued investor confidence in the company's governance and strategic direction. The article, however, requires login to …

Jazz Pharmaceuticals (NASDAQ: JAZZ) posts full 2026 AGM voting results

Jazz Pharmaceuticals plc announced the results of its 2026 annual general meeting held in Dublin. Shareholders approved the election of three directors, the appointment of KPMG, Dublin as independent auditors, and the compensation of named executive officers on a non-binding basis. Additionally, shareholders granted …

Jazz Pharmaceuticals PLC $JAZZ is Systematic Financial Management LP's 5th Largest Position

Systematic Financial Management LP increased its stake in Jazz Pharmaceuticals PLC (JAZZ) by 2.6% in Q1, making it their 5th largest position. Institutional ownership of JAZZ is very high at 89.14%, with several major investors recently boosting their holdings. Wall Street sentiment for Jazz …

Jazz Pharmaceuticals’ 43-week Trend Signal approaches its high as volume thins

JAZZ closed just 1.2% below its 52-week high after a 26.0% quarter, but the latest advance came on only 0.7x normal volume and activity pressure has cooled from June levels.

Does AZZ’s Raised 2027 Sales Outlook Amid Weaker Q1 Earnings Change The Bull Case For AZZ (AZZ)?

AZZ Inc. reported weaker first-quarter earnings with net income falling significantly, though sales increased year-over-year. Despite the decline in profit, the company raised its full-year fiscal 2027 sales outlook to US$1.80 billion–US$1.85 billion, signaling management's confidence in future performance. This move highlights the company's …

Jazz Pharmaceuticals stock hits all-time high at 250.85 USD By Investing.com

Jazz Pharmaceuticals PLC stock has reached an all-time high at $250.85, reflecting a significant 1-year change of 114.77% and a market capitalization of $15.71 billion. Despite this, InvestingPro analysis suggests the company is undervalued relative to its fair value, boasting impressive gross profit margins …

Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?

Jazz Pharmaceuticals sets Aug. 3 webcast after market close

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to review results and provide a business and …

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

Jazz Pharmaceuticals plc announced it will report its second-quarter 2026 financial results on Monday, August 3, 2026, after the close of U.S. financial markets. The company's management will host a webcast at 4:30 p.m. ET to discuss the results and provide business and financial …

Did Jazz’s Sleep and Oncology Pipeline Momentum Just Shift Jazz Pharmaceuticals' (JAZZ) Investment Narrative?

Jazz Pharmaceuticals' investment narrative is gaining fresh attention from investors who are re-evaluating its sleep-disorder and oncology portfolios. The focus is on the company's pipeline progress, particularly with AXS-12's FDA filing and its broader sleep-disorder franchise, alongside its push into targeted rare cancer therapies. …

AZZ jumps 8% after raising FY2027 outlook on robust metal coatings demand

AZZ Inc. (AZZ) shares rose 8% after the company raised its financial outlook for fiscal year 2027, now projecting adjusted earnings per share of $6.00 to $6.50 and revenue between $1.6 billion and $1.7 billion. This positive revision is attributed to strong growth in …

AZZ (AZZ) Stock Could Be 25% Overvalued Despite Raised 2027 Guidance

Despite a strong 247% return over the last three years and positive recent performance, AZZ (NYSE:AZZ) stock appears overvalued by approximately 25% based on a Discounted Cash Flow (DCF) intrinsic value estimate. While its P/E ratio is in line with the industry average, suggesting …

Jazz Pharmaceuticals (JAZZ) Q1 2026 earnings summary

Jazz Pharmaceuticals (JAZZ) reported record Q1 2026 revenues of $1.1 billion, a 19% year-over-year increase, driven by strong growth in its sleep, epilepsy, and oncology portfolios. The company achieved a net income of $293.1 million, a significant improvement from a Q1 2025 net loss, …

Jazz Pharmaceuticals (JAZZ) Stock Still Looks Like A Bargain After A 119% Run

Jazz Pharmaceuticals (JAZZ) has seen a significant 119.3% return over the past year, prompting an evaluation of its current valuation. Despite this strong performance, Simply Wall St's analysis suggests the stock appears undervalued on several measures, trading at a P/S ratio (3.5x) below its …

Jazz Pharmaceuticals (JAZZ) Refocuses Its Sleep Franchise, Is The Stock Still Cheap?

Jazz Pharmaceuticals (JAZZ) Proxy filing Summary

Jazz Pharmaceuticals (JAZZ) has released its proxy filing summary for an annual general meeting (AGM) scheduled for July 23, 2026. Shareholders of record by May 28, 2026, are eligible to vote on director nominees and five other proposals, with the board recommending a "FOR" …

JAZZ PHARMACEUTICALS PLC : CANACCORD GENUITY INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $290

Canaccord Genuity has initiated coverage on Jazz Pharmaceuticals PLC (JAZZ.O) with a "BUY" rating. The firm has set a target price of $290 for the company's shares. This report originated from Reuters and was published on July 17, 2026, at 04:40.

Como fica a Azzas 2154 (AZZA3) sem a Farm – e por que o grupo considera vender a marca, na visão de gestores

AZZ (AZZ) Q1 2026 earnings summary

AZZ (AZZ) reported record Q1 2026 sales of $422M and adjusted EBITDA of $106.4M, with net income surging to $170.9M due to a $165.8M gain from the AVAIL JV distribution. The company raised its fiscal 2026 guidance for sales, adjusted EBITDA, and adjusted diluted …

Is Jazz Pharmaceuticals (JAZZ) Still Undervalued On Its Oncology And Neuroscience Growth Story?

Jazz Pharmaceuticals (JAZZ) has shown strong share price performance and revenue growth, leading to a narrative that pegs it as 7.4% undervalued with a fair value of $257.00. This optimism stems from the expected approval and launch of new therapies, particularly within its oncology …

Ultrapar (UGPA3) lidera altas da semana no Ibovespa; Azzas 2154 (AZZA3) tem a maior queda do período

Azzas 2154 (AZZA3) cai quase 6% nesta sexta (26); o que está no radar?

Jazz Pharmaceuticals loses short-term rank while its 39-week Trend Signal stays intact

JAZZ has cooled from a near-high run, with volume and Market Dynamics no longer confirming the earlier advance even as the weekly trend remains constructive.

Azzas 2154 (AZZA3): JP Morgan vê venda da Hering como 'improvável', mas um fator pode mudar isso; ações caem 3%

Ações da Azzas 2154 (AZZA3) disparam 10% com potencial venda da Farm Rio no radar; o que agradou?

Day trade: Compre B3 (B3SA3) e venda AZZAS 2154 (AZZA3) para ganhar até 1,51% hoje (29), segundo a Ágora

Azzas 2154 (AZZA3): Ações saltam com possível cisão entre Jatahy e Birman; JP Morgan acende alerta para governança

Azzas 2154 (AZZA3), Itaú (ITUB3), Brava Energia (BRAV3) e outros destaques desta quarta-feira (13)

Azzas 2154 (AZZA3): O impacto da briga entre entre Jatahy e Birman, segundo Citi

Day trade: Compre Brava Energia (BRAV3) e venda AZZAS 2154 (AZZA3) para ganhar até 1,48% hoje (8), segundo a Ágora

Ações da Azzas 2154 (AZZA3): vale a pena investir na antiga Arezzo?

Citi rebaixa Azzas 2154 (AZZA3) e corta R$ 17 do preço-alvo; entenda por que a ação está fora de moda para os analistas

Arezzo&Co mudará de nome para Azzas 2154 após fusão com Grupo Soma

AZZA3 - Ações Azzas 2154 ON | Cotação Hoje - Investing.com Brasil